Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis

Cancer
Robert S SvatekYair Lotan

Abstract

The Prostate Cancer Prevention Trial (PCPT) demonstrated that finasteride reduces the prevalence of prostate cancer by 24.8% (risk reduction) but questions remain regarding the cost-effectiveness of widespread utilization. The purpose of the current analysis was to evaluate the cost-effectiveness of chemoprevention utilizing a quality-of-life adjustment. A Markov decision analysis model with probabilistic sensitivity analysis was designed to determine the lifetime prostate health-related costs, beginning at age 50 years, for men treated with finasteride compared with placebo. Model assumptions were based on data from the PCPT; Surveillance, Epidemiology, and End-Results program; literature review of costs, utilities, and transition rates among various prostate cancer health states; and local institutional cost data. The quality-adjusted cost-effectiveness ratio for finasteride compared with men not receiving chemoprevention was $122,747 (in U.S.$) per quality-adjusted life-years saved (QALYs). If finasteride is assumed to not increase the incidence of high-grade tumors, the quality-adjusted cost-effectiveness ratio was $112,062 per QALYs. Sensitivity analysis found that chemoprevention of prostate cancer with an agent that has ...Continue Reading

References

Jul 1, 1985·American Journal of Public Health·C C WhiteW A Orenstein
May 30, 1998·Journal of the National Cancer Institute·M W KattanP T Scardino
Aug 6, 1998·The New England Journal of Medicine·J C Wright, M C Weinstein
May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
Oct 28, 1999·PharmacoEconomics·N MittmannB A Liu
Jan 27, 2000·JAMA : the Journal of the American Medical Association·J L StanfordA L Potosky
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·R A HirthW G Weissert
Nov 4, 2000·Journal of the National Cancer Institute·A M BayoumiA M Garber
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·N Y PiperT Seay
Dec 24, 2002·Prostate Cancer and Prostatic Diseases·R M BenoitM J Naslund
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Jul 30, 2003·Archives of Internal Medicine·Peter A UbelA Mark Fendrick
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yair LotanScott M Lippman
Mar 22, 2005·Medical Care·Susan T StewartRobert M Kaplan
Aug 9, 2005·The American Journal of Medicine·Steven B ZeliadtScott D Ramsey
May 16, 2006·The Journal of Urology·Phyllis J GoodmanCharles A Coltman
Aug 10, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Robert S SvatekYair Lotan
Aug 17, 2006·Journal of the National Cancer Institute·Ian M ThompsonCharles A Coltman
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian M ThompsonCharles A Coltman

❮ Previous
Next ❯

Citations

Jan 13, 2012·World Journal of Urology·Eric A Klein, Ian M Thompson
Aug 28, 2010·Nature Reviews. Clinical Oncology·Wesley M White, Edward D Kim
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J VickersHans Lilja
Jun 23, 2012·The Oncologist·Channing J Paller, Thomas J Smith
Aug 27, 2009·Therapeutics and Clinical Risk Management·Angela B Smith, Culley C Carson
Sep 17, 2011·BMC Medicine·Robert J Hamilton, Stephen J Freedland
Mar 11, 2010·Current Opinion in Urology·Seth A Strope, Gerald L Andriole
Oct 19, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Steven B Zeliadt, Scott D Ramsey
Dec 2, 2008·Expert Opinion on Drug Metabolism & Toxicology·Cosimo De NunzioAndrea Tubaro
Jul 4, 2015·Health Technology Assessment : HTA·Craig R RamsayThomas B Lam
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruchika GuttStanley L Liauw
Jan 10, 2018·Cold Spring Harbor Perspectives in Medicine·J Ricardo RiveroDharam Kaushik
Jun 10, 2011·Journal of Public Health Dentistry·Joan M O'Connell, Susan Griffin
Sep 10, 2014·Oncology Letters·John M Lacy, Natasha Kyprianou
Jun 12, 2010·Expert Opinion on Drug Metabolism & Toxicology·Uzair B Chaudhary, Jeffrey S Turner
Aug 12, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Robert J HamiltonLinda S Kinsinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.